Nurix Therapeutics develops novel therapies that modulate protein levels through small molecule drugs targeting E3 ligases. Nurix’s pipeline is focused on developing drugs for immune-mediated diseases and hematologic cancers including immuno-oncology therapeutics. Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors and corporate partners. The company is headquartered in San Francisco, California.

Foresite Capital believes that Nurix’s differentiated drug screening platform and novel therapeutic targeting approach positions the company as a leader in the emerging protein modulation field.